The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
On Tuesday, the agency sent warning letters to 10 pharmaceutical companies threatening legal action for improperly listed patents, and notified the FDA that it disputes the accuracy or relevance of ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in ...